YDES Healthcare

YD Bio Ltd

$6.39+7.12%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: Taiwan
Market cap: 453.0M USD
Enterprise value: 413.1M USD
Full-time employees: 13

Overall health

Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: higher risk than most peers on debt, liquidity or share-price swings
Not enough data: growth

Would rank #1,155 of 1,157 fully scored healthcare companies (bottom 1%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Negative shareholders' equity. Liabilities exceed assets on the balance sheet.
YD Bio's liabilities exceed its assets on the balance sheet. Large share buybacks can cause this in healthy companies, but so can accumulated losses; either way, debt-based ratios need care.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, YD Bio looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to December 2025.
YD Bio reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.
Financials may be out of date. Latest financial period ended 10 months ago.
The latest financial period we have ended 10 months ago, so the scores may not reflect recent results.

StockQuotient Score

6/ 100

Oct 5 6 → Nov 4 6

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-1.8%

SEC filings · 12 months to Dec 2025Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-1.2%

SEC filings · 12 months to Dec 2025Negative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-1.8%

SEC filings · 12 months to Dec 2025 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield-0.6%

SEC filings · latest balance sheetOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

4/100

Weak

3/3 inputs reported · High confidence

Why

Weaker than most peers on:

▼ Operating margin
▼ ROA
▼ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-883.3%

SEC filings · 12 months to Dec 2025Outlier capped at sector 5th/95th percentile33% base weight · Z-score -71.87Sector median: 0.0706 · MAD: 0.1217

Return on assets-60.3%

SEC filings · 12 months to Dec 2025Outlier capped at sector 5th/95th percentile33% base weight · Z-score -11.22Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-1.2%

Yahoo Finance fallback · SEC operating income or invested capital unavailable · trailing 12 monthsReported value33% base weight · Z-score -0.59Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin28.1%

SEC filings · 12 months to Dec 2025Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equityUnavailable

Missing · left out of the scoreInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

2/3 inputs reported · Partial data

Why

Weaker than most peers on:

▼ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

BetaUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.6250 · MAD: 0.3380

Current ratio5.88×

SEC filings · latest balance sheetReported value33% base weight · Z-score 2.38Sector median: 2.5860 · MAD: 1.3850

Debt / equityUnavailable

Shareholders' equity is negative, so debt/equity counts as among the highest in its peer group33% base weight · Z-score -9.77Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about YD Bio

Is YD Bio getting weaker?: A comparison of its latest SEC filing with the previous one isn't available yet. Its overall score is unchanged at 6/100 since Oct 28, 2026.
How is YD Bio valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -1.8% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -1.8% vs peers 1.5% (weaker than 100% of peers).
Is YD Bio growing?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How profitable is YD Bio?: Less profitable than most of its peers. Profitability scores 4/100 against 1,393 healthcare peers. Operating margin -883.3% vs a peer median of 7.1% (weaker than 100% of peers).Operating margin -883.3% vs peers 7.1% (weaker than 100% of peers).
How risky is YD Bio?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 5.88× vs a peer median of 2.59× (stronger than 78% of peers).Current ratio 5.88× vs peers 2.59× (stronger than 78% of peers). A relative measure, not a bankruptcy probability.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2023	FY 2024	FY 2025	Change
Gross margin	43.8%	30.4%	28.1%	▼ 2.4 pts
Operating margin	-2.8%	-286.5%	-883.3%	▼ 597 pts
Net margin	3.9%	-276.6%	-1392.6%	▼ >999 pts
Return on assets (ROA)	—	-20.6%	-60.3%	▼ 40 pts
Return on equity (ROE)	59.0%	-21.4%	—	—
Free cash flow margin	-16.0%	-254.3%	-1346.6%	▼ >999 pts
Current ratio	—	13.18×	5.88×	▼ 55%
Quick ratio	—	13.04×	4.74×	▼ 64%
Interest coverage	-4.59×	-1893.69×	—	—

YDES price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: higher risk than most peers on debt, liquidity or share-price swings

Not enough data: growth

Would rank #1,155 of 1,157 fully scored healthcare companies (bottom 1%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Negative shareholders' equity. Liabilities exceed assets on the balance sheet.

YD Bio's liabilities exceed its assets on the balance sheet. Large share buybacks can cause this in healthy companies, but so can accumulated losses; either way, debt-based ratios need care.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, YD Bio looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to December 2025.

YD Bio reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Financials may be out of date. Latest financial period ended 10 months ago.

The latest financial period we have ended 10 months ago, so the scores may not reflect recent results.

Questions investors ask about YD Bio

Is YD Bio getting weaker?

A comparison of its latest SEC filing with the previous one isn't available yet. Its overall score is unchanged at 6/100 since Oct 28, 2026.

How is YD Bio valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -1.8% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -1.8% vs peers 1.5% (weaker than 100% of peers).

Is YD Bio growing?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How profitable is YD Bio?

Less profitable than most of its peers. Profitability scores 4/100 against 1,393 healthcare peers. Operating margin -883.3% vs a peer median of 7.1% (weaker than 100% of peers).Operating margin -883.3% vs peers 7.1% (weaker than 100% of peers).

How risky is YD Bio?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 5.88× vs a peer median of 2.59× (stronger than 78% of peers).Current ratio 5.88× vs peers 2.59× (stronger than 78% of peers). A relative measure, not a bankruptcy probability.

Key ratios

FY 2023

FY 2024

FY 2025

Change

Gross margin

43.8%

30.4%

28.1%

▼ 2.4 pts

Operating margin

-2.8%

-286.5%

-883.3%

▼ 597 pts

Net margin

3.9%

-276.6%

-1392.6%

▼ >999 pts

Return on assets (ROA)

—

-20.6%

-60.3%

▼ 40 pts

Return on equity (ROE)

59.0%

-21.4%

—

Free cash flow margin

-16.0%

-254.3%

-1346.6%

▼ >999 pts

Current ratio

—

13.18×

5.88×

▼ 55%

Quick ratio

—

13.04×

4.74×

▼ 64%

Interest coverage

-4.59×

-1893.69×

—